Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination.
Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination.
复制标题
SARS-CoV-2刺突蛋白保守抗原表位在感染和疫苗接种后产生的交叉反应抗体
DOI：
10.1038/s41598-022-10230-y
复制
发表时间：
2022-04-20
影响因子：
4.6
通讯作者：
Bradley, Todd
中科院分区：
文献类型：
--
作者：
Geanes, Eric S.;LeMaster, Cas;Fraley, Elizabeth R.;Khanal, Santosh;McLennan, Rebecca;Grundberg, Elin;Selvarangan, Rangaraj;Bradley, Todd
SARS-CoV-2 是一种新型 β 冠状病毒，引起 2019 年冠状病毒病，已导致全球数百万人死亡。人类新型冠状病毒感染已逐渐变得更加普遍。了解针对 SARS-CoV-2 的抗体反应，并识别冠状病毒株之间保守的交叉反应表位，可以为具有广泛应用的疫苗和治疗方法的设计提供信息。在这里，我们确定曾感染过 SARS-CoV-2 或接种过辉瑞 BioNTech BNT162b2 疫苗的个体会产生与相关 β 冠状病毒发生交叉反应的抗体反应。此外，我们设计了一种具有保守的 SARS-CoV-2 S2 刺突表位的肽结合疫苗，对小鼠进行免疫，并确定了与 SARS-CoV-2 和其他相关冠状病毒结合的交叉反应抗体。这种保守的刺突表位还与共生肠道微生物群中的蛋白质具有序列同源性，并且可以引发人类的免疫反应。因此，SARS-CoV-2 保守表位会引发对相关冠状病毒和宿主细菌的交叉反应性免疫反应，这些反应可以作为广泛的冠状病毒治疗和疫苗的未来目标。
SARS-CoV-2 is a novel betacoronavirus that caused coronavirus disease 2019 and has resulted in millions of deaths worldwide. Novel coronavirus infections in humans have steadily become more common. Understanding antibody responses to SARS-CoV-2, and identifying conserved, cross-reactive epitopes among coronavirus strains could inform the design of vaccines and therapeutics with broad application. Here, we determined that individuals with previous SARS-CoV-2 infection or vaccinated with the Pfizer-BioNTech BNT162b2 vaccine produced antibody responses that cross-reacted with related betacoronaviruses. Moreover, we designed a peptide-conjugate vaccine with a conserved SARS-CoV-2 S2 spike epitope, immunized mice and determined cross-reactive antibody binding to SARS-CoV-2 and other related coronaviruses. This conserved spike epitope also shared sequence homology to proteins in commensal gut microbiota and could prime immune responses in humans. Thus, SARS-CoV-2 conserved epitopes elicit cross-reactive immune responses to both related coronaviruses and host bacteria that could serve as future targets for broad coronavirus therapeutics and vaccines.
登录
查看更多内容
影响因子：
5.4
作者：
Figueiredo-Campos P;Blankenhaus B;Mota C;Gomes A;Serrano M;Ariotti S;Costa C;Nunes-Cabaço H;Mendes AM;Gaspar P;Pereira-Santos MC;Rodrigues F;Condeço J;Escoval MA;Santos M;Ramirez M;Melo-Cristino J;Simas JP;Vasconcelos E;Afonso Â;Veldhoen M
通讯作者：
Veldhoen M
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
9.3
作者：
Fraley E;LeMaster C;Geanes E;Banerjee D;Khanal S;Grundberg E;Selvarangan R;Bradley T
通讯作者：
Bradley T
影响因子：
24.1
作者：
Li Y;Lai DY;Lei Q;Xu ZW;Wang F;Hou H;Chen L;Wu J;Ren Y;Ma ML;Zhang B;Chen H;Yu C;Xue JB;Zheng YX;Wang XN;Jiang HW;Zhang HN;Qi H;Guo SJ;Zhang Y;Lin X;Yao Z;Pang P;Shi D;Wang W;Yang X;Zhou J;Sheng H;Sun Z;Shan H;Fan X;Tao SC
通讯作者：
Tao SC
影响因子：
9.4
作者：
Lau, Susanna K. P.;Woo, Patrick C. Y.;Yuen, Kwok-yung
通讯作者：
Yuen, Kwok-yung